Recent Advances in Amyotrophic Lateral Sclerosis Research: Perspectives for Personalized Clinical Application

Overview

Journal EPMA J

Date 2012 Dec 4

PMID 23199069

Citations 9

Authors

Chen Benkler

Daniel Offen

Eldad Melamed

Lana Kupershmidt

Tamar Amit

Silvia Mandel

Moussa B H Youdim

Orly Weinreb

Affiliations

Soon will be listed here.

Abstract

Treatment of amyotrophic lateral sclerosis (ALS) has been fueled, in part, by frustration over the shortcomings of the symptomatic drugs available, since these do not impede the progression of this disease. Currently, over 150 different potential therapeutic agents or strategies have been tested in preclinical models of ALS. Unfortunately, therapeutic modifiers of murine ALS have failed to be successfully translated into strategies for patients, probably because of differences in pharmacokinetics of the therapeutic agents, route of delivery, inefficiency of the agents to affect the distinct pathologies of the disease or inherent limitations of the available animal models. Given the multiplicity of the pathological mechanisms implicated in ALS, new therapies should consider the simultaneous manipulation of multiple targets. Additionally, a better management of ALS therapy should include understanding the interactions between potential risk factors, biomarkers and heterogeneous clinical features of the patients, aiming to manage their adverse events or personalize the safety profile of these agents. This review will discuss novel pharmacological approaches concerning adjusted therapy for ALS patients: iron-binding brain permeable multimodal compounds, genetic manipulation and cell-based treatment.

Citing Articles

Mesenchymal stem cell therapy in amyotrophic lateral sclerosis (ALS) patients: A comprehensive review of disease information and future perspectives.

Najafi S, Najafi P, Farkhad N, Hosseini Torshizi G, Assaran Darban R, Boroumand A Iran J Basic Med Sci. 2023; 26(8):872-881.

PMID: 37427325 PMC: 10329242. DOI: 10.22038/IJBMS.2023.66364.14572.

Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis.

McGurk L, Mojsilovic-Petrovic J, Van Deerlin V, Shorter J, Kalb R, Lee V Acta Neuropathol Commun. 2018; 6(1):84.

PMID: 30157956 PMC: 6114235. DOI: 10.1186/s40478-018-0586-1.

Synthesis and Cytoprotective Characterization of 8-Hydroxyquinoline Betti Products.

Kanizsai I, Madacsi R, Hackler Jr L, Gyuris M, Szebeni G, Huzian O Molecules. 2018; 23(8).

PMID: 30072653 PMC: 6222637. DOI: 10.3390/molecules23081934.

Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease.

Unzeta M, Esteban G, Bolea I, Fogel W, Ramsay R, Youdim M Front Neurosci. 2016; 10:205.

PMID: 27252617 PMC: 4879129. DOI: 10.3389/fnins.2016.00205.

Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis.

Golko-Perez S, Mandel S, Amit T, Kupershmidt L, Youdim M, Weinreb O Neurotox Res. 2015; 29(2):208-17.

PMID: 26581376 DOI: 10.1007/s12640-015-9574-4.

References

Molz S, Decker H, Dal-Cim T, Cremonez C, Cordova F, Leal R . Glutamate-induced toxicity in hippocampal slices involves apoptotic features and p38 MAPK signaling. Neurochem Res. 2007; 33(1):27-36. DOI: 10.1007/s11064-007-9402-1. View

Weinreb O, Amit T, Mandel S, Youdim M . Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr. 2009; 4(4):283-96. PMC: 2775893. DOI: 10.1007/s12263-009-0143-4. View

Cho G, Noh M, Kim H, Koh S, Kim K, Kim S . Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev. 2009; 19(7):1035-42. DOI: 10.1089/scd.2009.0453. View

Wang X, Lee S, Simmons Z, Boyer P, Scott K, Liu W . Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci. 2004; 227(1):27-33. DOI: 10.1016/j.jns.2004.08.003. View

Engelhardt J, Soos J, Obal I, Vigh L, Siklos L . Subcellular localization of IgG from the sera of ALS patients in the nervous system. Acta Neurol Scand. 2005; 112(2):126-33. DOI: 10.1111/j.1600-0404.2005.00445.x. View

Qin D, Zou X, Luo W, Zhang W, Zhang H, Li X . Expression of some neurotrophins in the spinal motoneurons after cord hemisection in adult rats. Neurosci Lett. 2006; 410(3):222-7. DOI: 10.1016/j.neulet.2006.10.006. View

Wang L, Lu Y, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T . Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci. 2002; 22(16):6920-8. PMC: 6757879. DOI: 20026668. View

Xu L, Ryugo D, Pongstaporn T, Johe K, Koliatsos V . Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol. 2009; 514(4):297-309. PMC: 2727711. DOI: 10.1002/cne.22022. View

Bahat-Stroomza M, Barhum Y, Levy Y, Karpov O, Bulvik S, Melamed E . Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. J Mol Neurosci. 2009; 39(1-2):199-210. DOI: 10.1007/s12031-008-9166-3. View

10.

Garbuzova-Davis S, Willing A, Milliken M, Saporta S, Zigova T, Cahill D . Positive effect of transplantation of hNT neurons (NTera 2/D1 cell-line) in a model of familial amyotrophic lateral sclerosis. Exp Neurol. 2002; 174(2):169-80. DOI: 10.1006/exnr.2002.7860. View

11.

Brooks B . Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol. 2009; 65 Suppl 1:S17-23. DOI: 10.1002/ana.21544. View

12.

Lambrechts D, Carmeliet P . VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta. 2006; 1762(11-12):1109-21. DOI: 10.1016/j.bbadis.2006.04.005. View

13.

Semenza G . Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 1999; 59(1):47-53. DOI: 10.1016/s0006-2952(99)00292-0. View

14.

Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W . Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002; 13(8):1067-70. DOI: 10.1097/00001756-200206120-00018. View

15.

Brand K . Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr. 1997; 29(4):355-64. DOI: 10.1023/a:1022498714522. View

16.

Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H . Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007; 21(14):3835-44. DOI: 10.1096/fj.07-8386com. View

17.

Francois S, Bensidhoum M, Mouiseddine M, Mazurier C, Allenet B, Semont A . Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells. 2005; 24(4):1020-9. DOI: 10.1634/stemcells.2005-0260. View

18.

Lepore A, Haenggeli C, Gasmi M, Bishop K, Bartus R, Maragakis N . Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007; 1185:256-65. PMC: 2265207. DOI: 10.1016/j.brainres.2007.09.034. View

19.

Gal S, Zheng H, Fridkin M, Youdim M . Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res. 2009; 17(1):15-27. DOI: 10.1007/s12640-009-9070-9. View

20.

Pierce R, BARI A . The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci. 2001; 12(2):95-110. DOI: 10.1515/revneuro.2001.12.2.95. View